Current examples include the clinical development of Atorvastatin (anti-PCSK9) for the treatment of hypercholesterolemia [2]and Gevokizumab (anti-Il-1β) for type 2 diabetes [3], as well as the preclinical advancement of antibodies targeting FGFR1 [4], the insulin receptor [5] and the glucagon receptor [6] for type 2 diabetes. Here, FGFR1 is linked to type 2 diabetes mellitus.